

[Chem. Pharm. Bull.]
31(8)2708—2711(1983)]

Monoamine Oxidase Inhibitor from the Rhizomes of *Kaempferia galanga* L.¹⁾

TADATAKA NORO,* TOSHIO MIYASE, MASANORI KUROYANAGI,
AKIRA UENO and SEIGO FUKUSHIMA

Shizuoka College of Pharmacy, 2-2-1, Oshika, Shizuoka 422, Japan

(Received January 21, 1983)

Monoamine oxidase (MAO) inhibitor contained in the rhizomes of *Kaempferia galanga* L. (Zingiberaceae) was isolated and identified as ethyl *p*-methoxy-*trans*-cinnamate (I). The type of inhibition with respect to benzylamine by I was competitive.

Keywords—monoamine oxidase; inhibitor; competitive inhibitor; benzylamine; *Kaempferia galanga*; Zingiberaceae; ethyl *p*-methoxy-*trans*-cinnamate; *p*-methoxy-*trans*-cinnamic acid

The purpose of this study was not only the development of new medicinal drugs but also to examine the effects of traditional oriental drugs. Inhibitors of monoamine oxidase (MAO, EC 1.4.3.4) are candidates as drugs for the treatment of depression.

In screening tests *in vitro* aiming to find MAO inhibitors from many crude oriental drugs and plant materials, the rhizomes of *Kaempferia galanga* L. (Japanese name, "sanna", Zingiberaceae) were found to possess a strong inhibitory effect on this enzyme. The rhizomes of *Kaempferia galanga* have been used as an aromatic stomachic and an incense. The constituents of the rhizomes hitherto reported are ethyl *p*-methoxycinnamate, ethyl cinnamate, cinnamaldehyde, camphene, *l*- Δ^3 -carene, borneol, *p*-methoxystyrene and penta-decane.²⁾ In this paper, we describe the isolation of a MAO inhibitor from the rhizomes of *Kaempferia galanga*.

Results and Discussion

The activity of MAO towards benzylamine as a substrate was assayed spectrophotometrically at 250 nm by the method of Tabor *et al.*³⁾ with a slight modification. The rhizomes of *Kaempferia galanga* were extracted with benzene, chloroform, acetone, methanol and water under reflux as shown in Chart 1. The inhibitory activity of each extract against MAO and the yields are shown in Chart 1. The most active (benzene) extract was fractionated by silica gel column chromatography with a hexane–benzene–acetone gradient system, and the fractions were monitored by thin layer chromatography (TLC) and also by measurement of inhibitory activity against MAO. The most active fraction of the benzene extract was recrystallized from hexane to give an active compound as colorless prisms (I), mp 47 °C. This was identical with synthetic ethyl *p*-methoxy-*trans*-cinnamate on the basis of melting point, spectral comparisons and elemental analysis. Compound I is a major constituent of the rhizomes. The concentration of I in the reaction mixture required to give 50% inhibition (IC₅₀) was 6.8×10^{-5} M.

Compound I was also obtained as the most active inhibitory principle against MAO from other extracts (chloroform ext., acetone ext. and methanol ext.). *p*-Methoxy-*trans*-cinnamic acid (II), which was obtained from the rhizomes at the same time, had essentially no effect on MAO at the same concentration.

Kinetic studies were done on the effect of I on the oxidation of benzylamine by MAO. The results are shown as Lineweaver–Burk plots⁴⁾ in Fig. 1. The type of inhibition by I was competitive. K_m of MAO for benzylamine was 1.39×10^{-3} M and the K_i value of I for oxidation of benzylamine by MAO was 3.04×10^{-5} M.

The types of inhibitor of MAO hitherto reported include hydrazines,⁵⁾ xanthenes,⁶⁾ chalcones,⁷⁾ amines,⁸⁾ alkaloids,⁸⁾ cinnamamide⁸⁾ and so on. The result obtained in this study shows that I is an inhibitor of a new structural type. We are synthesizing various cinnamic acid derivatives in addition to the above compounds, and extensive studies on their MAO inhibitory activities are in progress in our laboratory.




Chart 1




Fig. 1. Inhibitory Action of Ethyl *p*-Methoxy-*trans*-cinnamate (I) on MAO

Lineweaver–Burk plots in the absence (0 M, \times — \times) and in the presence (2.42×10^{-5} M, \bullet — \bullet) of I with benzylamine as a substrate. v , μmol substrate metabolized $\cdot\text{g}^{-1}$ enzyme $\cdot\text{min}^{-1}$; s , substrate.

Experimental

The following instruments were used to obtain physical data. Melting points were determined on a Yanagimoto melting point apparatus, and are uncorrected. The infrared (IR) spectra were recorded on a JASCO IR A-202 infrared spectrophotometer. The proton nuclear magnetic resonance (^1H -NMR) spectra and the carbon-13 nuclear magnetic resonance (^{13}C -NMR) spectra were recorded on a JEOL JNM-FX 90Q FT NMR spectrometer (90 MHz) with tetramethylsilane as an internal standard (δ value; s, singlet; d, doublet; t, triplet; q, quartet; br, broad). Mass spectra (MS) were recorded on a JEOL JMS-01SG-2 mass spectrometer. Silica gel 60 GF₂₅₄ (Merck) was used for TLC and detection was achieved by illumination with an ultraviolet lamp or by spraying 20% H_2SO_4 followed by

heating. For column chromatography, Silica gel 60 (Merck) was used. The spectrophotometric measurements were carried out with a Hitachi model 101 spectrophotometer.

Enzyme and Chemicals—Monoamine oxidase (EC 1.4.3.4) from bovine plasma was obtained from Sigma Chemical Co. Benzylamine and Tween 80 were obtained from Wako Pure Chemical Industries, Ltd. Sodium phosphate dibasic 12 hydrate and potassium phosphate monobasic were obtained from Kanto Chemical Co. Buffer was Sørensen's 0.2 M potassium phosphate–sodium phosphate buffer of pH 7.4. The substrate, 0.1 M benzylamine sulfate, was prepared immediately before use as follows. Benzylamine (1.07 g), which had been purified by re-distillation, and 2 N H₂SO₄ (5 ml) were dissolved in H₂O to make 100 ml of solution. Enzyme solution containing about 0.02 unit per ml in 0.2 M potassium phosphate buffer of pH 7.4 was prepared immediately before use.

Test Solution—When the test samples were not easily soluble in water, they were dissolved in ethanol and Tween 80, and diluted with water to give final concentrations of 3% (v/v) for ethanol and 1.5% (w/v) for Tween 80 in the assay mixtures. At these concentrations of ethanol and Tween 80, MAO activities were little affected.

Assay of Monoamine Oxidase Activity—The MAO activities with benzylamine as a substrate were measured spectrophotometrically by the method of Tabor *et al.*³⁾ with a slight modification. Test solution (1.0 ml), 0.2 M potassium phosphate buffer (4.8 ml) and enzyme solution (0.1 ml) were mixed and preincubated at 25 °C for 15 min. After this, the substrate (0.1 ml) was added to the assay mixture and the whole was incubated at 25 °C for 30 min. Then, 1 N HCl (1.0 ml) was added to stop the reaction. The absorbance of the reaction mixture was measured spectrophotometrically at 250 nm. A blank was prepared in the same way, but the enzyme solution was added to the assay mixture after adding 1 N HCl.

Estimation of Percent Inhibition—The percent inhibition of the oxidative reaction was calculated by the method of Aoyagi *et al.*⁹⁾

Extraction and Separation—The dried rhizomes (1 kg, commercial product) of *Kaempferia galanga* were extracted three times with 3 l of benzene under reflux for 3 h, then with CHCl₃, acetone, methanol and H₂O in the same way, and the extracts were each concentrated *in vacuo*. These extracts were assayed for inhibitory effects on MAO. The yields and inhibitory activities are shown in Chart 1. These extracts were each fractionated by silica gel column chromatography with a hexane–benzene–acetone gradient system. The eluates were monitored by TLC and also by measurement of inhibitory activity against MAO. The most active fraction (eluted with hexane:benzene = 1:1, v/v) of the benzene extract was purified by recrystallization from hexane to give the active compound as colorless prisms (I). The eluate with benzene:acetone (1:1, v/v) of the benzene extract gave pale yellow prisms (II) from EtOH. Compound I was also obtained as the most active principle against MAO from other extracts (CHCl₃ ext., acetone ext. and MeOH ext.).

Ethyl *p*-Methoxy-*trans*-cinnamate (I)—Colorless prisms from hexane, mp 47 °C (lit. mp 48–50 °C).²⁾ IR (KBr) cm⁻¹: 1715, 1635, 1610, 1180, 838. MS *m/z* (rel. int. %): 206 (M⁺, 55), 161 (100), 134 (62), 133 (53), 118 (26), 90 (22), 89 (35), 77 (22), 63 (24). ¹H-NMR (CDCl₃) δ: 1.30 (3H, t, *J* = 7.2 Hz), 3.74 (3H, s), 4.22 (2H, q, *J* = 7.2 Hz), 6.26 (1H, d, *J* = 15.9 Hz), 6.83 (2H, d, *J* = 8.6 Hz), 7.40 (2H, d, *J* = 8.6 Hz), 7.61 (1H, d, *J* = 15.9 Hz). ¹³C-NMR (CDCl₃) δ: 14.34 (q), 55.21 (q), 60.20 (t), 114.37 (d), 115.89 (d), 127.27 (s), 129.65 (d), 144.17 (d), 161.49 (s), 167.07 (s). *Anal.* Calcd for C₁₂H₁₄O₃: C, 69.88; H, 6.84. Found: C, 69.99; H, 6.71. This was identical with synthetic ethyl *p*-methoxy-*trans*-cinnamate on the basis of mp, spectral comparisons and elemental analysis. Compound I is the major constituent of the rhizomes.

***p*-Methoxy-*trans*-cinnamic Acid (II)**—Pale yellow prisms from EtOH, mp 173 °C (lit. mp 171–172 °C).²⁾ *Anal.* Calcd for C₁₀H₁₀O₃: C, 67.40; H, 5.16. Found: C, 67.51; H, 5.14. This was identical with synthetic *p*-methoxy-*trans*-cinnamic acid on the basis of mp, spectral comparisons and elemental analysis.

Lineweaver–Burk Plots⁴⁾—Lineweaver–Burk plots for MAO under our assay conditions were obtained in the absence and in the presence of I using benzylamine as a substrate, as shown in Fig. 1.

Acknowledgement The authors thank Dr. Mitsuo Uchida and Mrs. Hisayo Kitamura, Analytical Center of Shizuoka College of Pharmacy, for the MS measurements and elemental analysis.

References and Notes

- 1) T. Noro, T. Miyase, M. Kuroyanagi, A. Ueno and S. Fukushima, Abstracts of Papers, the 102nd Annual Meeting of the Pharmaceutical Society of Japan, Osaka, April 1982, p. 544.
- 2) M. Nakao and C. Shibue, *Yakugaku Zasshi*, **44**, 913 (1924); P. M. B. Paniker, B. S. Rao and J. L. Simonsen, *J. Indian Inst. Sci.*, **9A**, 133 (1926); [*Chem. Abstr.*, **21**, 798⁵ (1927)]; Research Institute for Drugs of Chinese Medical and Technological College *et al.*, “Zhōng-yào-zhi, 中藥志,” Vol. 1, Rénmínwèishēng Pub. Co., Peking, 1961, p. 50.
- 3) C. W. Tabor, H. Tabor and S. M. Rosenthal, *J. Biol. Chem.*, **208**, 645 (1954).
- 4) H. Lineweaver and D. Burk, *J. Am. Chem. Soc.*, **56**, 658 (1934).
- 5) K. Nishinuma, *Seishin Shinkeigaku Zasshi*, **65**, 614 (1963); [*Chem. Abstr.*, **64**, 18272c (1966)]; K. Yamamoto and F. Hirata, Japan Patent 26675 (1963); [*Chem. Abstr.*, **60**, 11948b (1964)].

- 6) O. Suzuki, Y. Katsumata, M. Oya, V. M. Chari, B. Vermes, H. Wagner and K. Hostettmann, *Planta Medica*, **42**, 17 (1981).
- 7) S. Tanaka, Y. Kuwai and M. Tabata, Abstracts of Papers, The 100th Annual Meeting of the Pharmaceutical Society of Japan, Tokyo, April 1980, p. 239.
- 8) T. Takeuchi, K. Ogawa, H. Iinuma, H. Suda, K. Ukita, T. Nagatsu, M. Kato, H. Umezawa and O. Tanabe, *J. Antibiot.*, **26**, 162 (1973).
- 9) T. Aoyagi, S. Miyata, M. Nanbo, F. Kojima, M. Matsuzaki, M. Ishizuka, T. Takeuchi and H. Umezawa, *J. Antibiot.*, **22**, 558 (1969).